Biodegradable macromolecular CT contrast agents

可生物降解高分子CT造影剂

基本信息

  • 批准号:
    8790640
  • 负责人:
  • 金额:
    $ 19.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-01 至 2016-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The goal of this research project is to design and develop novel iodinated polysulfides as biodegradable macromolecular blood pool X-ray computed tomography (CT) contrast agents. There is an unmet clinical need for safe and effective blood pool contrast agents for clinical diagnostic imaging and image-guided interventions. Currently clinical agents have a transient blood half-life. High dose and multiple injections are often used to generate sufficient contrast enhancement in many clinical protocols. However, high dose may cause contrast-induced nephropathy. Although nanosized CT have agents have been reported, their clinical use is limited by the safety concerns associated their slow clearance from the body. In this exploratory research project, we propose to develop novel biodegradable macromolecular blood pool CT contrast agents to address the limitations of clinical CT agents and nanosized agents and the unmet clinical need. We will first design, synthesize and characterize iodinated polysulfides as biodegradable macromolecular blood pool CT contrast agents and determine their in vitro and in vivo degradability and clearance in an animal model in the specific aim 1, and then determine the effectiveness of the novel blood pool CT contrast agents for cardiovascular imaging, cancer imaging and quantitative perfusion imaging in an animal tumor model in the specific aim 2. Our long-term goal is to develop a safe and effective biodegradable macromolecular blood pool CT contrast agent for clinical cardiovascular imaging, cancer imaging, perfusion imaging and image- guided interventions.
描述(由申请人提供):本研究项目的目标是设计和开发新型碘化多硫化物作为可生物降解的大分子血池x射线计算机断层扫描(CT)造影剂。临床对安全有效的血池造影剂用于临床诊断成像和图像引导干预的需求尚未得到满足。目前临床药物的血液半衰期是短暂的。在许多临床方案中,经常使用高剂量和多次注射来产生足够的对比增强。然而,高剂量可引起造影剂肾病。尽管纳米级CT具有显像剂的报道,但由于其从体内清除缓慢的安全性问题,其临床应用受到限制。在本探索性研究项目中,我们提出开发新型可生物降解的大分子血池CT造影剂,以解决临床CT造影剂和纳米级造影剂的局限性和临床未满足的需求。我们将首先设计、合成并表征作为可生物降解的大分子血池CT造影剂的碘化多硫化物,并在特定目标1中确定其在动物模型中的体外和体内降解性和清除率,然后在特定目标2中确定新型血池CT造影剂在动物肿瘤模型中用于心血管成像、癌症成像和定量灌注成像的有效性。我们的长期目标是开发一种安全有效的可生物降解的大分子血池CT造影剂,用于临床心血管成像、癌症成像、灌注成像和图像引导干预。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ZHENG-RONG LU其他文献

ZHENG-RONG LU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ZHENG-RONG LU', 18)}}的其他基金

Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
  • 批准号:
    10307922
  • 财政年份:
    2021
  • 资助金额:
    $ 19.37万
  • 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
  • 批准号:
    10300425
  • 财政年份:
    2018
  • 资助金额:
    $ 19.37万
  • 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
  • 批准号:
    10524128
  • 财政年份:
    2018
  • 资助金额:
    $ 19.37万
  • 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
  • 批准号:
    10755865
  • 财政年份:
    2018
  • 资助金额:
    $ 19.37万
  • 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
  • 批准号:
    10532735
  • 财政年份:
    2018
  • 资助金额:
    $ 19.37万
  • 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
  • 批准号:
    10054176
  • 财政年份:
    2018
  • 资助金额:
    $ 19.37万
  • 项目类别:
Targeted MRI contrast agents for differential diagnosis of prostate cancer
靶向 MRI 造影剂用于前列腺癌的鉴别诊断
  • 批准号:
    9327104
  • 财政年份:
    2017
  • 资助金额:
    $ 19.37万
  • 项目类别:
Targeted MRI contrast agents for differential diagnosis of prostate cancer
靶向 MRI 造影剂用于前列腺癌的鉴别诊断
  • 批准号:
    9903251
  • 财政年份:
    2017
  • 资助金额:
    $ 19.37万
  • 项目类别:
Image-guided EMT inhibition for treating metastatic breast cancer
图像引导 EMT 抑制治疗转移性乳腺癌
  • 批准号:
    9301500
  • 财政年份:
    2015
  • 资助金额:
    $ 19.37万
  • 项目类别:
Biodegradable macromolecular CT contrast agents
可生物降解高分子CT造影剂
  • 批准号:
    8870352
  • 财政年份:
    2014
  • 资助金额:
    $ 19.37万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 19.37万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.37万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 19.37万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.37万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 19.37万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.37万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 19.37万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 19.37万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 19.37万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.37万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了